Minerva Neurosciences Toekomstige groei

Future criteriumcontroles 0/6

De verwachting is dat Minerva Neurosciences de winst en omzet met respectievelijk 44.2% en 88% per jaar zal laten groeien, terwijl de winst per aandeel naar verwachting zal groeien met 37.4% per jaar.

Belangrijke informatie

44.2%

Groei van de winst

37.4%

Groei van de winst per aandeel

Biotechs winstgroei	28.5%
Inkomstengroei	88.0%
Toekomstig rendement op eigen vermogen	n/a
Dekking van analisten	Low
Laatst bijgewerkt	06 Nov 2024

Recente toekomstige groei-updates

Recent updates

Minerva says FDA declined to accept marketing application for schizophrenia drug

Oct 17

Is Minerva Neurosciences (NASDAQ:NERV) In A Good Position To Deliver On Growth Plans?

Jan 26

Here's Why We're Not Too Worried About Minerva Neurosciences' (NASDAQ:NERV) Cash Burn Situation

Oct 02

Minerva Neurosciences' (NASDAQ:NERV) Shareholders Are Down 59% On Their Shares

Mar 03

What You Need To Know About Minerva Neurosciences, Inc.'s (NASDAQ:NERV) Investor Composition

Jan 27

We're Keeping An Eye On Minerva Neurosciences' (NASDAQ:NERV) Cash Burn Rate

Dec 23

A Potential Trade Arises On Minerva

Dec 09

A Look At Minerva Neurosciences' (NASDAQ:NERV) Share Price Returns

Nov 18

Minerva Neurosciences EPS beats by $0.03

Nov 02

Winst- en omzetgroeiprognoses

NasdaqCM:NERV - Toekomstschattingen van analisten en financiële gegevens uit het verleden (USD Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
12/31/2026	N/A	-46	N/A	N/A	1
12/31/2025	N/A	-30	N/A	N/A	1
12/31/2024	N/A	-2	N/A	N/A	1
9/30/2024	N/A	-3	-20	-20	N/A
6/30/2024	N/A	-34	-21	-21	N/A
3/31/2024	N/A	-32	-21	-21	N/A
12/31/2023	N/A	-30	-15	-15	N/A
9/30/2023	N/A	-28	-13	-13	N/A
6/30/2023	N/A	-27	-18	-18	N/A
3/31/2023	N/A	-29	-19	-19	N/A
12/31/2022	N/A	-32	-25	-25	N/A
9/30/2022	N/A	-47	-25	-25	N/A
6/30/2022	N/A	-49	-24	-24	N/A
3/31/2022	N/A	-51	-25	-25	N/A
12/31/2021	N/A	-50	-25	-25	N/A
9/30/2021	N/A	-36	-27	-27	N/A
6/30/2021	N/A	-35	-28	-28	N/A
3/31/2021	41	5	-30	-30	N/A
12/31/2020	41	2	-34	-34	N/A
9/30/2020	41	-21	-41	-41	N/A
6/30/2020	41	-27	-40	-40	N/A
3/31/2020	N/A	-69	-43	-43	N/A
12/31/2019	N/A	-72	-43	-43	N/A
9/30/2019	N/A	-55	-39	-39	N/A
6/30/2019	N/A	-54	-40	-40	N/A
3/31/2019	N/A	-54	-41	-41	N/A
12/31/2018	N/A	-50	-42	-42	N/A
9/30/2018	N/A	-37	-41	-41	N/A
6/30/2018	N/A	-36	N/A	-6	N/A
3/31/2018	N/A	-33	N/A	-2	N/A
12/31/2017	N/A	-32	N/A	3	N/A
9/30/2017	N/A	-41	N/A	3	N/A
6/30/2017	N/A	-38	N/A	-26	N/A
3/31/2017	N/A	-34	N/A	-26	N/A
12/31/2016	N/A	-31	N/A	-26	N/A
9/30/2016	N/A	-30	N/A	-23	N/A
6/30/2016	N/A	-28	N/A	-24	N/A
3/31/2016	N/A	-29	N/A	-25	N/A
12/31/2015	N/A	-27	N/A	-24	N/A
9/30/2015	N/A	-26	N/A	-23	N/A
6/30/2015	N/A	-47	N/A	-44	N/A
3/31/2015	N/A	-60	N/A	-40	N/A
12/31/2014	N/A	-57	N/A	-36	N/A
9/30/2014	N/A	-52	N/A	-32	N/A
6/30/2014	N/A	-25	N/A	-5	N/A
3/31/2014	N/A	-6	N/A	-3	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachting is dat NERV de komende 3 jaar verliesgevend zal blijven.

Winst versus markt: De verwachting is dat NERV de komende 3 jaar verliesgevend zal blijven.

Hoge groeiwinsten: De verwachting is dat NERV de komende 3 jaar verliesgevend zal blijven.

Omzet versus markt: Er wordt verwacht dat NERV volgend jaar geen omzet zal hebben.

Hoge groei-inkomsten: Er wordt verwacht dat NERV volgend jaar geen omzet zal hebben.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Onvoldoende gegevens om te bepalen of het rendement op eigen vermogen van NERV naar verwachting over 3 jaar hoog zal zijn

Minerva Neurosciences Toekomstige groei

Future criteriumcontroles 0/6

Belangrijke informatie

Recente toekomstige groei-updates

Price target decreased to US$6.67

Price target increased to US$8.33

Consensus revenue estimates fall to US$400.0k

Consensus forecasts updated

Analysts update estimates

Recent updates

Minerva Neurosciences, Inc., Annual General Meeting, Dec 05, 2024

Minerva Neurosciences Receives Second Written Notice from Nasdaq Regarding Non-Compliance with the Minimum Market Value of Listed Securities Requirement under Nasdaq Listing Rule 5550(b)(2)

Minerva Neurosciences Receives Notice from Nasdaq Regarding Non-Compliance with the Minimum Market Value of Listed Securities Requirement Nasdaq's Listing Rule 5550(b)(2)

Minerva Neurosciences, Inc., Annual General Meeting, Sep 27, 2023

Minerva Neurosciences, Inc. announced that it expects to receive $19.999994 million in funding from Frazier Healthcare Partners, Boehringer Ingelheim International GmbH

Nasdaq Determines to Delist Minerva Neurosciences' Securities from The Nasdaq Capital Market

Minerva Neurosciences, Inc. to Report Q1, 2023 Results on May 15, 2023

Minerva Neurosciences, Inc. Announces Board Changes

Minerva Neurosciences, Inc. Announces Update on its New Drug Application (NDA) for Roluperidone for the Treatment of Negative Symptoms in Schizophrenia

Minerva Neurosciences Receives Non-Compliance Notice from The Nasdaq Stock Market LLC

Minerva Neurosciences, Inc. to Report Q3, 2022 Results on Nov 09, 2022

Minerva Neurosciences, Inc. Receives Refusal to File Letter from FDA for its New Drug Application for Roluperidone for the Treatment of Negative Symptoms in Schizophrenia

Minerva says FDA declined to accept marketing application for schizophrenia drug

Minerva Neurosciences: Biotech On The Move

Minerva Neurosciences, Inc. Submits New Drug Application to Fda for Roluperidone for the Treatment of Negative Symptoms in Patients with Schizophrenia

Minerva stock rises on filing for FDA approval of schizophrenia therapy

We're Hopeful That Minerva Neurosciences (NASDAQ:NERV) Will Use Its Cash Wisely

Insufficient new directors

Minerva Neurosciences Provides Update from Type C Meeting with FDA and Next Steps in Preparation for Submission of New Drug Application for Roluperidone for the Treatment of Negative Symptoms in Schizophrenia

Price target decreased to US$6.67

Minerva Neurosciences, Inc. Announces Publication of Roluperidone Phase 3 Study Results in Schizophrenia Bulletin

Is Minerva Neurosciences (NASDAQ:NERV) In A Good Position To Deliver On Growth Plans?

Price target increased to US$8.33

Here's Why We're Not Too Worried About Minerva Neurosciences' (NASDAQ:NERV) Cash Burn Situation

Consensus revenue estimates fall to US$400.0k

Minerva Neurosciences, Inc.(NasdaqGM:NERV) dropped from Russell 3000E Growth Index

Investor sentiment improved over the past week

Consensus forecasts updated

Minerva Neurosciences, Inc. Announces the Results of the Phase 3 Trial of Roluperidone for the Treatment of Negative Symptoms of Schizophrenia Following the Completion of the 40-Week Open-Label Extension

Investor sentiment deteriorated over the past week

Analysts update estimates

Earnings beat expectations, revenue disappoints

Minerva Neurosciences' (NASDAQ:NERV) Shareholders Are Down 59% On Their Shares

Minerva Neurosciences, Inc. to Report Q4, 2020 Results on Mar 08, 2021

What You Need To Know About Minerva Neurosciences, Inc.'s (NASDAQ:NERV) Investor Composition

Bernstein Liebhard LLP Reminds Investors in SPLK, NAK, and NERV of Filing Deadlines

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Minerva Neurosciences, Inc

We're Keeping An Eye On Minerva Neurosciences' (NASDAQ:NERV) Cash Burn Rate

New 90-day low: US$2.58

Block & Leviton LLP Announces That It Has Filed A Lawsuit Against Minerva Neurosciences, Inc. for Securities Fraud

A Potential Trade Arises On Minerva

A Look At Minerva Neurosciences' (NASDAQ:NERV) Share Price Returns

New 90-day high: US$3.59

Earnings miss expectations

Minerva Neurosciences EPS beats by $0.03

Minerva Neurosciences, Inc. to Report Q3, 2020 Results on Nov 02, 2020

New 90-day low - US$3.21

Minerva Neurosciences, Inc.(NasdaqGM:NERV) dropped from Russell Microcap Value Index

Winst- en omzetgroeiprognoses

Toekomstige groeivoorspellingen analisten

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Ontdek groeibedrijven